Such studies will begin to answer the question of whether these genetic variants should be considered in studies examining whether biomarkers are able to help predict those at greatest risk of developing ARDS and whether agents that modify CFTR function might be therapeutically useful in a subset of patients at risk of developing ARDS. Here, CFTR is linked to acute respiratory distress syndrome.